RetinalGenix Technologies develops ultra-high-resolution retinal imaging technology combined with genetic testing and advanced analytics for ophthalmic screening, monitoring, pharmacogenetic mapping, and early disease detection. Company updates commonly address the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, non-invasive retinal imaging, biomarker research, and the use of retinal data in oculomics for ocular and systemic disease applications.
Recurring developments include research collaborations in proteomics and genotyping, laboratory-services support for genetic and retinal health screening, patent activity for home and remote ocular monitoring, and work tied to conditions such as age-related macular degeneration, glaucoma, diabetic retinopathy, Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative or systemic disorders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.